Pharmaceutical marketing for rare diseases: Regulating drug company promotion in an era of unprecedented advertisement

JAMA - Journal of the American Medical Association

Volumn 317, Issue 24, 2017, Pages 2479-2480

  Mailankody, Sham ^a   Prasad, Vinay ^b,c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; RUXOLITINIB; JAK2 PROTEIN, HUMAN; PYRAZOLE DERIVATIVE;

ADVERTISING; DIAGNOSTIC ERROR; DIAGNOSTIC TEST; DIRECT-TO-CONSUMER ADVERTIZING; DRUG APPROVAL; DRUG INDUSTRY; DRUG MARKETING; DRUG USE; FOOD AND DRUG ADMINISTRATION; HUMAN; MYELOPROLIFERATIVE NEOPLASM; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PUBLIC HEALTH; RARE DISEASE; SHORT SURVEY; ART; AWARENESS; GENETICS; HEALTH SERVICE; LEGISLATION AND JURISPRUDENCE; MARKETING; MYELOPROLIFERATIVE DISORDERS; PATIENT ATTITUDE; PRESCRIPTION; PROCEDURES; PSYCHOLOGY; RARE DISEASES; STANDARDS; TELEVISION; UNITED STATES;

ADVERTISING AS TOPIC; AWARENESS; DIRECT-TO-CONSUMER ADVERTISING; DRUG INDUSTRY; DRUG PRESCRIPTIONS; HUMANS; JANUS KINASE 2; MARKETING; MEDICAL OVERUSE; MEDICINE IN ART; MYELOPROLIFERATIVE DISORDERS; PATIENT ACCEPTANCE OF HEALTH CARE; POLYCYTHEMIA VERA; PYRAZOLES; RARE DISEASES; TELEVISION; UNITED STATES;

EID: 85021284130     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2017.5784     Document Type: Short Survey

References (10)

1. ABC. Anna's diagnosis. General Hospital. 2017. https://www.youtube.com/watch?v=PHHh-i0XaDU. Accessed May 10, 2017.
2. Anía BJ, Suman VJ, Sobell JL, Codd MB, Silverstein MN, Melton LJ III. Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935-1989. Am J Hematol. 1994;47(2):89-93.
3. Incyte raises awareness for myeloproliferative neoplasms as part of Rare Disease Day [press release]. February 28, 2017. http://www.businesswire.com/news/home/20170228005457/en/Incyte-Raises-Awareness-Myeloproliferative-Neoplasms-Part-Rare. Accessed May 10, 2017.
4. 't Jong GW, Stricker BHC, Sturkenboom MCJM. Marketing in the lay media and prescriptions of terbinafine in primary care: Dutch cohort study. BMJ. 2004;328(7445):931.
5. Layton JB, Kim Y, Alexander GC, Emery SL. Association between direct-to-consumer advertising and testosterone testing and initiation in the United States, 2009-2013. JAMA. 2017;317(11):1159-1166.
6. Spivak JL, Silver RT. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood. 2008;112(2):231-239.
7. McCaffrey K. Drugmakers again boost DTC spending, to $5.6 billion in 2016. March 3, 2017. http://www.mmm-online.com/commercial/drugmakers-again-boost-dtc-spending-to-56-billion-in-2016/article/642028/. Accessed May 10, 2017.
8. Snyder Bulik B. BMS' Opdivo jumps back into pharma's top 3 TV ad spenders for November. December 12, 2016. http://www.fiercepharma.com/marketing/opdivo-jumps-back-into-top-three-pharma-tv-ad-spenders-for-november. Accessed May 10, 2017.
9. Snyder Bulik B. Valeant, AstraZeneca played the Super Bowl ad game, but did they win? February 8, 2016. http://www.fiercepharma.com/marketing/valeant-astrazeneca-played-super-bowl-ad-game-but-did-they-win. Accessed May 10, 2017.
10. Sharfstein JM, Charo A. The promotion of medical products in the 21st century: off-label marketing and First Amendment concerns. JAMA. 2015;314(17):1795-1796.